Pharm-Olam Completes Birch and Grass Pollen Allergy Studies - 2 x Phase II, Full Service, Europe, Dose Escalation
Pharm-Olam Completes Birch and Grass Pollen Allergy Studies - 2 x Phase II, Full Service, Europe, Dose Escalation
2 PagesCASE STUDY I. Grass Pollen Allergy Protocol Overview: Randomised, double-blind, placebo- controlled, multicentre, 5-arm, staggered start Subjects with allergic rhinitis/rhinoconjunctivitis related to grass pollen Summary of Inclusion/Exclusion Criteria: Inclusion criteria: Allergic rhinitis/conjunctivitis related to grass pollen, positive SPT for grass pollen, positive serum specific anti-grass IgE-test, a positive TNPT for grass pollen at screening Exclusion Criteria: Clinically relevant symptoms due to concomitant sensitisation to allergens other than grass pollen, patients sensitized to pets, prior successful immunotherapy thin past 5 years, prior unsuccessful immunotherapy Study Participation: 266 patients enrolled at 23 sites in Germany and Poland in 2.5 months Study Time
